Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 5/20 | 0.43 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.43 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5358451 | 0.85 | HSP90AA1 (0.45) | ALDH1A1RECQLGLAHSP90AA1APOBEC3A | |
| SCHEMBL5445229 | 0.79 | ALDH1A1 (0.57) | ALDH1A1RECQLGLAHTTTSHR | |
| Bromide SCHEMBL7514295 | 0.79 | ALDH1A1 (0.76) | ALDH1A1RECQLGLAHTTTSHR | |
| SCHEMBL12205239 | 0.77 | ALDH1A1 (0.64) | ALDH1A1RECQLGLAHTTTSHR | |
| SCHEMBL5367449 | 0.74 | ALDH1A1 (0.62) | ALDH1A1RECQLGLAHTTHSP90AA1 | |
| SCHEMBL10307403 | 0.73 | ALDH1A1 (0.59) | ALDH1A1RECQLGLAHTTTSHR | |
| Bromide SCHEMBL9155378 | 0.73 | NPSR1 (0.62) | ALDH1A1RECQLGLAHTTTSHR | |
| SCHEMBL10307413 | 0.71 | ALDH1A1 (0.57) | ALDH1A1RECQLGLAHTTTSHR | |
| SCHEMBL3841660 | 0.71 | ALDH1A1 (0.57) | ALDH1A1RECQLGLAHTTTSHR | |
| Bromide SCHEMBL4504186 | 0.70 | ALDH1A1 (0.56) | ALDH1A1RECQLGLAHTTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007132179-A2 | THERAPEUTICS COMPRISING PYRIDINIUM DERIVATIVES | UNIVERSITY OF BATH (GB) | 2007-11-22 | — | — | WO | disclosed |
| US-20070105810-A1 | THERAPEUTICS | POTTER BARRY V L | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105810-A1 | THERAPEUTICS | RYR1, ATP2A1, CACNA1E | ALDH1A1 2886/4885RECQL 2324/4885GLA 1336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.